FDA clears AstraZeneca’s Etcamah for advanced breast cancer
AstraZeneca’s oral breast cancer drug Etcamah has secured accelerated approval from the US Food and Drug Administration for a defined group of patients with advanced disease, despite an earlier negative vote by the regulator’s oncology advisory panel. The FDA authorised Etcamah, or camizestrant, with a CDK4/6 inhibitor for adults with hormone receptor-positive, HER2-negative locally advanced or…
We haven't written up this one. Arabian Post has the full story — the link below goes straight to it.
